Oncolytic Viruses: Now interviewing for the all-star game

Molecular Therapy

Volumn 18, Issue 5, 2010, Pages 866-868

  Vile, Richard ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC VACCINIA VIRUS; ONCOLYTIC VIRUS; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; DRUG EFFICACY; GENETIC ENGINEERING; IMMUNE RESPONSE; INNATE IMMUNITY; NOTE; ONCOLYTIC VIROTHERAPY; TUMOR CELL DESTRUCTION; VESICULAR STOMATITIS VIRUS; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS INFECTION; VIRUS RECOMBINATION; VIRUS REPLICATION;

EID: 77951996421     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2010.60     Document Type: Note

References (11)

1. Pandha, H, Melcher, A, Harrington, K and Vile, R (2009). Oncolytic viruses: time to compare, contrast, and combine? 5th International Meeting on Replicating Oncolytic Virus Therapeutics. Banff, Alberta, Canada, 18-22 March 2009. Mol Ther 17:934-935.
2. Le Boeuf, F, Diallo, J.-S., McCart, JA, Thorne, S, Falls, T, Stanford, M et al. (2010). Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther 18:888-895.
3. Cattaneo, R, Miest, T, Shashkova, EV and Barry, MA (2008). Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 6:529-540.
4. Mulhern, O, Harrington, B and Bowie, AG (2009). Modulation of innate immune signalling pathways by viral proteins. Adv Exp Med Biol 666:49-63.
5. McCart, JA, Ward, JM, Lee, J, Hu, Y, Alexander, HR, Libutti, SK et al. (2001). Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 61:8751-8757.
6. Stojdl, DF, Lichty, BD, Knowles, S, Marius, R, Atkins, H, Sonenberg, N et al. (2000). Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 6:821-825.
7. Stojdl, DF, Lichty, BD, tenOever, BR, Paterson, JM, Power, AT, Knowles, S, et al. (2003). VSV strains with defects in their ability to shut down innate immunity are potent systemic anti-cancer agents. Cancer Cell 4:263-275.
8. Perdiguero, B and Esteban, M (2009). The interferon system and vaccinia virus evasion mechanisms. J Interferon Cytokine Res 29:581-598.
9. Zeh, HJ and Bartlett, DL (2002). Development of a replication-selective, oncolytic-poxvirus for the treatment of human cancers. Cancer Gene Ther 9:1001-1012.
10. Colamonici, OR, Domanski, P, Sweitzer, SM, Larner, A and Buller, RM (1995). Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. J Biol Chem 270:15974-15978.
11. Brown, CW, Stephenson, KB, Hanson, S, Kucharczyk, M, Duncan, R, Bell, JC et al. (2009). The p14 FAST protein of reptilian reovirus increases vesicular stomatitis virus neuropathogenesis. J Virol 83:552-561.